Zepbound outperformed Nordisk's Wegovy in terms of weight loss, solidifying Lilly's leadership in the anti-obesity drug ...

Eli Lilly signs a global licensing deal with Rznomics to co-develop RNA-editing therapies for hearing loss, with potential ...

While many pharma and biotech companies developing drugs to treat Alzheimer's disease are targeting amyloid beta plaque, Eli ...

Eli Lilly (NYSE: LLY) was an unstoppable bet in the past few years, but LLY stock finally started plateauing in the latter ...

The deal gives Lilly access to the company’s RNA-editing platform to develop therapies for sensorineural hearing loss.

A consultancy’s new ranking of drug company R&D shows Eli Lilly has risen to the top of the drug development heap, while ...

Eli Lilly (LLY) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some ...

Eli Lilly recently announced the impressive results of its SURMOUNT-5 trial, highlighting Zepbound's efficacy over Wegovy in weight management. This promising development was disclosed alongside ...

President Donald Trump vowed to impose tariffs on pharmaceuticals within two weeks. Eli Lilly, a leader in the industry, could be harmed by the move, but it is already preparing for it.

From late 2020 to the summer of 2024, Eli Lilly & Co. (NYSE: LLY) stock was on a tear, up more than 635%. Last year was a transformative year for the Indianapolis-based pharmaceutical giant ...

Eli Lilly said its Zepbound obesity drug helped patients reduce their waist size by an extra two inches compared to those on Novo Nordisk’s Wegovy in a head-to-head study of the two drugs.